Spectranetics Corporation (Nasdaq:SPNC) today announced that the Ministry of Health, Labor and Welfare in Japan has approved product reimbursement to hospitals for the Spectranetics Laser Sheath (SLS® II), which is used for the removal of problematic pacemaker and defibrillator cardiac leads.
Through the Company's distribution partner, DVx Inc., the initial phase of the product launch will commence immediately and focus on establishing a limited number of lead extraction training centers.
Emile J. Geisenheimer, Chairman, President and Chief Executive Officer, stated, "Japan represents a significant market opportunity for our products. Product reimbursement for our SLS II is an important accomplishment as it is our first product to have both regulatory and reimbursement approval in Japan. We have regulatory submissions pending for certain peripheral atherectomy, crossing solutions, and lead locking device products, and through our partnership with DVx, look forward to offering our full portfolio of products in the future."
Esketamine after childbirth cuts risk of postnatal depression by three-quarters